Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

By P. Neumann, Joshua T. Cohen, M. Weinstein. New England Journal of Medicine, 2014

2,057 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “Conventionally the threshold adopted by most agencies in the last couple of decades has been US $50,000 per year of life saved,(88) although either slightly lower (£30,000) or significantly higher levels (up to $150,000) have been proposed to account for inflation, specific national healthcare resou”
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016, background): “[5] Neumann PJ, Cohen JT, Weinstein MC.”
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe (2016, methodology): “QALYs lost were calculated as the difference between the projected QALYs in the NAFLD population and the projected QALYs in the general population, weighted by age, as sourced from the National Health Measurement study.((31,39-45)) This difference was then multiplied by the monetary value of a QALY.”